Detalles de la búsqueda
1.
Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotide.
Nature
; 619(7971): 811-818, 2023 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-37407817
2.
Full-length sequence analysis of hepatitis C virus genotype 3b strains and development of an in vivo infectious 3b cDNA clone.
J Virol
; 97(12): e0092523, 2023 Dec 21.
Artículo
Inglés
| MEDLINE | ID: mdl-38092564
3.
Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.
Gut
; 72(3): 560-572, 2023 03.
Artículo
Inglés
| MEDLINE | ID: mdl-35918103
4.
Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
Antimicrob Agents Chemother
; 65(7): e0009721, 2021 06 17.
Artículo
Inglés
| MEDLINE | ID: mdl-33903110
5.
Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
J Viral Hepat
; 28(2): 236-244, 2021 02.
Artículo
Inglés
| MEDLINE | ID: mdl-33058390
6.
Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
J Viral Hepat
; 28(2): 302-316, 2021 02.
Artículo
Inglés
| MEDLINE | ID: mdl-33131178
7.
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Hepatology
; 70(3): 771-787, 2019 09.
Artículo
Inglés
| MEDLINE | ID: mdl-30964552
8.
Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.
Scand J Gastroenterol
; 53(7): 849-856, 2018.
Artículo
Inglés
| MEDLINE | ID: mdl-29720023
9.
Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2.
Front Immunol
; 15: 1353353, 2024.
Artículo
Inglés
| MEDLINE | ID: mdl-38571939
10.
Pre-existing, treatment-specific resistance-associated substitutions in hepatitis C virus genotype 1 and 3 and viral RNA titers during treatment with direct-acting antivirals.
APMIS
; 131(8): 426-433, 2023 Aug.
Artículo
Inglés
| MEDLINE | ID: mdl-37355962
11.
Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.
EBioMedicine
; 89: 104475, 2023 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-36870117
12.
Myocardial perfusion reserve in patients with chronic hepatitis C before and after direct-acting antiviral treatment-a pilot study.
Clin Physiol Funct Imaging
; 42(6): 389-395, 2022 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-35766035
13.
Novel HCV Genotype 4d Infectious Systems and Assessment of Direct-Acting Antivirals and Antibody Neutralization.
Viruses
; 14(11)2022 11 15.
Artículo
Inglés
| MEDLINE | ID: mdl-36423136
14.
Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA-mRNA or Vector-mRNA COVID-19 Vaccines.
Vaccines (Basel)
; 10(1)2022 Jan 04.
Artículo
Inglés
| MEDLINE | ID: mdl-35062736
15.
Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
EBioMedicine
; 71: 103519, 2021 Sep.
Artículo
Inglés
| MEDLINE | ID: mdl-34419923
16.
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Eur J Gastroenterol Hepatol
; 30(10): 1177-1186, 2018 10.
Artículo
Inglés
| MEDLINE | ID: mdl-29994874
17.
Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
PLoS One
; 9(12): e113034, 2014.
Artículo
Inglés
| MEDLINE | ID: mdl-25438153
Resultados
1 -
17
de 17
1
Próxima >
>>